Alzheimer’s Biomarkers Identify Faster Cognitive Decline in Adults Over 80

As a result, memory complaints are often attributed to normal aging, potentially leaving underlying neurodegenerative disease undetected. Laboratory biomarkers that capture Alzheimer’s disease biology may help clarify prognosis in this population. New findings now demonstrate that cerebrospinal fluid (CSF) and blood markers can predict faster cognitive decline and dementia progression in very old adults with mild cognitive impairment.

Sant Pau Research Institute (IR Sant Pau; Barcelona, Spain) evaluated Alzheimer’s disease biomarker testing in CSF and blood to refine prognostication in people aged 80 and older with mild cognitive impairment (MCI). The approach defined Alzheimer’s disease biology using characteristic CSF proteins, including the ratio of phosphorylated tau 181 (p-Tau181) to beta-amyloid, alongside a blood-based correlate, p-Tau217. Because p-Tau217 can be measured from a blood sample, the method is presented as a simpler, more scalable alternative to lumbar puncture or amyloid positron emission tomography (PET) for broader clinical use.

The study analyzed 167 participants over age 80 with MCI from the Sant Pau Initiative on Neurodegeneration (SPIN) cohort, where patients undergo systematic biomarker evaluation. Baseline cognitive differences between those with and without Alzheimer’s biology were modest, particularly on memory tests. Outcomes during follow-up included Mini-Mental State Examination (MMSE) trajectories and progression to dementia, and the work was published in Neurology (2026).

Nearly 70% of participants showed biomarker profiles consistent with Alzheimer’s disease. Those with Alzheimer’s biology declined an average of 0.47 MMSE points per year compared with 0.18 points per year among those without evidence of the disease, indicating distinct clinical trajectories. Higher p-Tau217 concentrations were associated with a greater likelihood of progression to dementia over follow-up, with risk increases approaching 50% depending on biomarker levels.

The investigators emphasize that, even in very old adults with common comorbidities, confirming the underlying pathology provides meaningful prognostic information. In routine care, many patients over age 80 are still assessed without biomarkers, leaving uncertainty about the cause of their symptoms. As age increases, early cognitive differences between individuals with and without Alzheimer’s disease often become less pronounced, limiting the discriminatory capacity of clinical assessment and contributing to diagnostic and therapeutic nihilism.

The authors add that blood-based biomarkers could make testing more feasible in geriatric settings while supporting personalized care planning. The emergence of disease-modifying therapies further underscores the need for accurate early diagnosis, as these treatments may slow cognitive decline. The findings also question excluding people over age 80 from biomarker-based strategies and highlight the need for individualized assessment, since chronological age alone does not capture this population’s heterogeneity. For well-preserved patients with good functional status and longer life expectancy, a more precise diagnosis may have substantial clinical value.

Beyond diagnosis, identifying Alzheimer’s disease biology in older adults has direct relevance for clinical management. Establishing the cause of cognitive decline can help clinicians anticipate progression, tailor follow-up, and support medical and family planning, especially at a stage of life when these decisions are increasingly important.

“Not every memory problem after age 80 is normal, and assuming that it is can lead to the underdiagnosis of diseases such as Alzheimer’s,” said Ignacio Illán-Gala, a researcher with the Neurobiology of Dementias Group at Sant Pau Research Institute (IR Sant Pau), a neurologist at Sant Pau Hospital, and one of the study’s authors.

“Older patients often have many coexisting conditions that can impact memory, and relying solely on clinical assessment may lead to inaccurate diagnoses. In fact, approximately half of the cases do not correspond to pure Alzheimer’s disease, which means that, without biomarkers, it is difficult to determine what is causing the cognitive decline and to accurately anticipate its progression,” said Chiara Ceriello, a geriatrician at Sant Pau Hospital and first author of the article.

"The availability of a blood-based biomarker makes it much easier to incorporate this assessment into clinical practice, particularly for older patients," said Ceriello. "It allows us to obtain relevant biological information in a simpler and more practical way, and this has a direct impact on how we assess and monitor these patients."

Related Links:
Sant Pau Research Institute